vs
Idexx Laboratories(IDXX)とRXO, Inc.(RXO)の財務データ比較。上の社名をクリックして会社を切り替えられます
RXO, Inc.の直近四半期売上が大きい($1.5B vs $1.1B、Idexx Laboratoriesの約1.3倍)。Idexx Laboratoriesの純利益率が高く(22.8% vs -3.1%、差は25.9%)。Idexx Laboratoriesの前年同期比売上増加率が高い(14.3% vs -11.9%)。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い($326.3M vs $-9.0M)。過去8四半期でRXO, Inc.の売上複合成長率が高い(26.8% vs 6.4%)
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
RXO, Inc.は米国に本社を置く大手運輸・物流ソリューションプロバイダーです。中核事業には貨物仲介、大型商品のラストワンマイル配送、管理型輸送サービス、エンドツーエンドのサプライチェーン最適化支援があり、主に北米の製造業、小売業、Eコマース分野の顧客にサービスを提供しています。
IDXX vs RXO — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | ||
|---|---|---|
| 売上 | $1.1B | $1.5B |
| 純利益 | $248.2M | $-46.0M |
| 粗利率 | 60.3% | — |
| 営業利益率 | 28.9% | -2.9% |
| 純利益率 | 22.8% | -3.1% |
| 売上前年比 | 14.3% | -11.9% |
| 純利益前年比 | 14.8% | -84.0% |
| EPS(希薄化後) | $3.09 | $-0.28 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.1B | $1.4B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $998.4M | $1.4B | ||
| Q4 24 | $954.3M | $1.7B | ||
| Q3 24 | $975.5M | $1.0B | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $964.1M | $913.0M |
| Q4 25 | $248.2M | $-46.0M | ||
| Q3 25 | $274.6M | $-14.0M | ||
| Q2 25 | $294.0M | $-9.0M | ||
| Q1 25 | $242.7M | $-31.0M | ||
| Q4 24 | $216.1M | $-25.0M | ||
| Q3 24 | $232.8M | $-243.0M | ||
| Q2 24 | $203.3M | $-7.0M | ||
| Q1 24 | $235.6M | $-15.0M |
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — | ||
| Q1 24 | 61.5% | — |
| Q4 25 | 28.9% | -2.9% | ||
| Q3 25 | 32.1% | -0.5% | ||
| Q2 25 | 33.6% | — | ||
| Q1 25 | 31.7% | -2.1% | ||
| Q4 24 | 27.4% | -1.4% | ||
| Q3 24 | 31.2% | -1.9% | ||
| Q2 24 | 26.3% | — | ||
| Q1 24 | 31.0% | -1.3% |
| Q4 25 | 22.8% | -3.1% | ||
| Q3 25 | 24.8% | -1.0% | ||
| Q2 25 | 26.5% | -0.6% | ||
| Q1 25 | 24.3% | -2.2% | ||
| Q4 24 | 22.7% | -1.5% | ||
| Q3 24 | 23.9% | -23.4% | ||
| Q2 24 | 20.3% | -0.8% | ||
| Q1 24 | 24.4% | -1.6% |
| Q4 25 | $3.09 | $-0.28 | ||
| Q3 25 | $3.40 | $-0.08 | ||
| Q2 25 | $3.63 | $-0.05 | ||
| Q1 25 | $2.96 | $-0.18 | ||
| Q4 24 | $2.62 | $-0.17 | ||
| Q3 24 | $2.80 | $-1.81 | ||
| Q2 24 | $2.44 | $-0.06 | ||
| Q1 24 | $2.81 | $-0.13 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | ||
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $17.0M |
| 総負債低いほど良い | $450.0M | $387.0M |
| 株主資本純資産 | $1.6B | $1.5B |
| 総資産 | $3.4B | $3.3B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | 0.25× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.1M | $17.0M | ||
| Q3 25 | $208.2M | $25.0M | ||
| Q2 25 | $164.6M | $18.0M | ||
| Q1 25 | $164.0M | $16.0M | ||
| Q4 24 | $288.3M | $35.0M | ||
| Q3 24 | $308.6M | $55.0M | ||
| Q2 24 | $401.6M | $7.0M | ||
| Q1 24 | $397.4M | $7.0M |
| Q4 25 | $450.0M | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | $617.8M | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.6B | $1.6B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.6B | $1.7B | ||
| Q2 24 | $1.6B | $579.0M | ||
| Q1 24 | $1.6B | $582.0M |
| Q4 25 | $3.4B | $3.3B | ||
| Q3 25 | $3.4B | $3.2B | ||
| Q2 25 | $3.3B | $3.2B | ||
| Q1 25 | $3.2B | $3.3B | ||
| Q4 24 | $3.3B | $3.4B | ||
| Q3 24 | $3.4B | $3.4B | ||
| Q2 24 | $3.4B | $1.8B | ||
| Q1 24 | $3.4B | $1.8B |
| Q4 25 | 0.28× | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | 0.39× | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | ||
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $7.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | $-9.0M |
| FCFマージンFCF / 売上 | 29.9% | -0.6% |
| 設備投資強度設備投資 / 売上 | 2.7% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | — |
| 直近12ヶ月FCF直近4四半期 | $1.1B | $-8.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $355.8M | $7.0M | ||
| Q3 25 | $402.3M | $23.0M | ||
| Q2 25 | $185.7M | $23.0M | ||
| Q1 25 | $238.0M | $-2.0M | ||
| Q4 24 | $262.0M | $-7.0M | ||
| Q3 24 | $220.1M | $-7.0M | ||
| Q2 24 | $248.3M | $-5.0M | ||
| Q1 24 | $198.6M | $7.0M |
| Q4 25 | $326.3M | $-9.0M | ||
| Q3 25 | $371.2M | $9.0M | ||
| Q2 25 | $151.6M | $9.0M | ||
| Q1 25 | $207.9M | $-17.0M | ||
| Q4 24 | $232.8M | $-19.0M | ||
| Q3 24 | $192.0M | $-18.0M | ||
| Q2 24 | $215.0M | $-16.0M | ||
| Q1 24 | $168.3M | $-4.0M |
| Q4 25 | 29.9% | -0.6% | ||
| Q3 25 | 33.6% | 0.6% | ||
| Q2 25 | 13.7% | 0.6% | ||
| Q1 25 | 20.8% | -1.2% | ||
| Q4 24 | 24.4% | -1.1% | ||
| Q3 24 | 19.7% | -1.7% | ||
| Q2 24 | 21.4% | -1.7% | ||
| Q1 24 | 17.5% | -0.4% |
| Q4 25 | 2.7% | 1.1% | ||
| Q3 25 | 2.8% | 1.0% | ||
| Q2 25 | 3.1% | 1.0% | ||
| Q1 25 | 3.0% | 1.0% | ||
| Q4 24 | 3.1% | 0.7% | ||
| Q3 24 | 2.9% | 1.1% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 3.1% | 1.2% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 1.21× | — | ||
| Q3 24 | 0.95× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.84× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |